In treating patients with castration resistant prostate cancer (CRPC), enzalutamide, the second-27 generation androgen receptor (AR) antagonist, is an accepted standard of care. However, clinical 28 benefits are limited to a median time of 4.8 months because resistance inevitably emerges. To 29 determine the mechanism of treatment resistance, we carried out a RNA sequence analysis and 30 found increased expression levels of neuroendocrine markers in the enzalutamide-resistant LNCaP 31 human prostate cancer (CaP) cell line when compared to the parental cell line. Subsequent studies 32 demonstrated that TCF4, a transcription factor implicated in Wnt signaling, mediated 33 neuroendocrine differentiation (NED) in response to enzalutamide treatment and was elevated in 34 the enzalutamide-resistant LNCaP. In addition, we observed that PTHrP mediated enzalutamide 35 resistance in tissue culture and inducible TCF4 overexpression resulted in enzalutamide-resistance 36 in a mouse xenograft model. Finally, small molecule inhibitors of TCF4 or PTHrP partially 37 reversed enzalutamide resistance in CaP cells. When tissues obtained from men who died of 38 metastatic CaP were examined, a positive correlation was found between the expression levels of 39 TCF4 and PTHrP. Taken together, the current results indicate that TCF4 induces enzalutamide 40 resistance via NED in CaP. 42 Prostate cancer (CaP) is the most common non-cutaneous cancer diagnosed among men and the 43 second leading cause of male cancer deaths in the United States (1). In 2017, it is estimated that 44 26,730 men died from CaP. Although radiation and surgery are quite effective for localized disease, 45 approximately 30% eventually recur following a definitive therapy. More importantly, there is no 46 effective cure for men who present with metastatic CaP as the 5-year relative survival rate is only 47 29% (1). In patients with a metastatic disease, medical or surgical castration is generally the 48 accepted first-line therapy. Yet, castration-resistant prostate cancer (CRPC) eventually emerges 49 with a median time of 18-24 months (2, 3). Once CRPC develops, secondary hormonal 50 manipulation, immunotherapy, and chemotherapy are marginally effective and the average life 51 expectancy is ~5 years (4, 5).
Introduction
Quantitative RT-PCR and PCR 126 Total RNA was isolated with TRIzol LS reagent (Thermo Fisher Scientific, Waltham, MA, 127 USA), and 1-2 g of total RNA was used for synthesizing cDNA with High-Capacity cDNA Immunoblot analysis 140 CaP cells were collected and lysed with lysis buffer (20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 141 mM Na 2 EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM beta-142 glycerophosphate, 1 mM Na 3 VO 4 , 1 µg/ml leupeptin) containing 1 mM phenylmethylsulfonyl 143 fluoride (PMSF). Cell lysates were centrifuged and protein in the supernatant was measured. After 
RESULTS

183
Enzalutamide-resistant human CaP cell line exhibits NED
184
To investigate the mechanism of enzalutamide resistance in CaP cells, an enzalutamide-resistant 185 human CaP cell line was initially generated by continuously treating LNCaP with 10 M 186 enzalutamide in RPMI-1640 supplemented with 10% charcoal stripped fetal bovine serum (cFBS).
187
After three months, cells began to proliferate consistently and were designated as LNCaP-EnzR.
188
Simultaneously, LNCaP cultured chronically under cFBS was also generated (LNCaP-cFBS).
189
With these cells, RNAseq followed by an unsupervised data analysis was carried out. When 190 compared to the LNCaP-cFBS, there was no obvious differences in AR signaling related gene 191 expression levels. However, NED markers such as chromogranin A (CHGA, ChgA), neuron-192 specific enolase (ENO2, NSE), and PTHrP (PTHLP) were significantly higher in LNCaP-EnzR ( Fig 1A) . A similar pattern of increased NED was observed in LNCaP-cFBS when compared to 194 the parental line maintained in the standard media (RPMI1640/10% FBS) ( Fig 1B) . To validate 195 these observations, we treated the human prostate cancer cell lines LNCaP and 22Rv1 with overexpressing TCF4 demonstrated significant increase in the mRNA levels of the NED markers 215 resistant to enzalutamide 10 M treatment as the cell number was nearly double that of the control 217 after three days of culture ( Fig 2B) . This resistance was not merely due to differentiation as TCF4-218 expressing cells continued to proliferate in the presence of enzalutamide. When the two 219 transcription factors were knocked down in LNCaP and 22Rv1 with shRNA, enzalutamide no 220 longer induced the expression of ChgA, NSE, and PTHrP proteins only when TCF4 expression 221 was blocked ( Fig 2C) . The kinetics of enzalutamide-induced TCF4 and NED markers expression 222 revealed that the increase in TCF4 mRNA preceded that of the NED markers by approximately 223 eight hours in tissue culture ( Fig 2D) . These results collectively demonstrate that TCF4 mediates 224 the expression of NED markers in human CaP cell lines. and VCaP-EnzR). Then, of the NED markers, we focused on PTHrP as a potential mediator of 230 enzalutamide resistance because this peptide has been demonstrated to mediate castration 231 resistance (18, 19) . Consistent with the published data reporting that TCF4 is a binding partner of 232 β-catenin (20, 21), pretreatment with the β-catenin degradation activator, XAV939 (22) at 10 M 233 five minutes prior to enzalutamide treatment, abrogated PTHrP mRNA induction by enzalutamide 234 in all three human CaP cell lines ( Fig 3A) . In addition to the ligand, we assessed whether the reported inhibitors -PKF118-310 and PTHrP (23, 24) . Both PKF118-310 and PTHrP significantly decreased the cellular proliferation of all three cell lines in a concentration-dependent 240 manner over a three-day period. Between the two inhibitors, PTHrP (7-34) had a more moderate 241 effect. In the three enzalutamide-resistant cell lines (LNCaP-EnzR, 22Rv1-EnzR, and VCaP-242 EnzR), PKF118-310 again inhibited the cellular proliferation in a concentration-dependent manner 243 up to 50 M after 3 days ( Fig 3C) . Similarly, PTHrP treatment also decreased cell count of 244 LNCaP-EnzR, 22Rv1-EnzR, and VCaP-EnzR in a concentration-dependent manner up to 1 mM 245 after 3 days. To assess whether PFK118-310 and PTHrP affected enzalutamide sensitivity, we 246 next cultured the three enzalutamide-resistant cell lines with a fixed concentration of PKF118-310 247 (5 μM) or PTHrP (7-34) (10 μM) and varying concentrations of enzalutamide (0-10 M). The results 248 demonstrated that both PKF118-310 and PTHrP reversed enzalutamide resistance in LNCaP-
249
EnzR, 22Rv1-EnzR, and VCaP-EnzR ( Fig 3D) . It should be noted that enzalutamide still exhibited 250 a concentration-dependent inhibitory effect on all three enzalutamide-resistant cell lines, 251 demonstrating that these cells have a relative and not an absolute resistance to enzalutamide.
252
Because TCF4 has been linked to Wnt signaling, we next examined the effect of typical frequently observed in CRPC tissues (Fig 4A) . PTHrP and TCF4 expression had positive 265 correlation ( Fig 4B) . Furthermore, metastatic CaP was found to express higher levels of TCF4 266 and PTHrP (Fig 4C and D, respectively) Fig 3A) . TCF4 induction slightly increased cellular proliferation but the difference was not 276 statistically significant (Supp Fig 3B) . As predicted based on our results, TCF4 induction resulted 277 in a relative resistance to enzalutamide up to 10 M when cultured over three days (Supp Fig 3C) .
278
In addition, tetracycline treatment stimulated the expression of NED markers, ChgA, NSE, and 279 PTHrP (Supp Fig 3D) .
280
When LNCaP-TCF4 was injected into flanks of Rag2-/-, c-/immunodeficient mice and 281 TCF4 expression was induced by doxycycline following surgical castration, a relative resistance 282 to enzalutamide treatment was observed over a six-week period ( Fig 5A) . There was no change in 283 histology among the harvested tumors regardless of the grouping (Fig 5B) . Immunofluorescence 284 microscopy demonstrated that enzalutamide treatment or TCF4 induction (doxy) increased the expression of the NED marker, PTHrP ( Fig 5C) . In addition, co-localization of TCF4 and PTHrP 286 was confirmed. Subsequently, immunoblot confirmed the immunofluorescence microscopy results 287 in that increased TCF4 and PTHrP proteins were observed in groups treated with either 288 enzalutamide or doxycycline ( Fig 5D) . QPCR demonstrated an increase in TCF4 and PTHrP 289 mRNA levels upon treatment with enzalutamide as well as doxycycline ( Fig 5E) . Collectively, 290 these results suggest that TCF4 renders CaP cells more aggressive. To study the therapeutic potential of targeting the TCF4/PTHrP axis, we carried out an in vivo 295 study with LNCaP-EnzR in mice. After establishing tumor xenografts, all animals underwent a 296 bilateral orchiectomy and were administered 10 mg/kg of enzalutamide via oral gavage daily. To 297 predesignated groups, 0.85 mg/kg of PKF-118-310, 0.2 mg/kg of PTHrP , or both in 298 combination were delivered daily. At the end of seven weeks, the results demonstrated that 299 PKF118-310 and PTHrP dramatically when combined with enzalutamide decreased the 300 tumor xenograft growth dramatically compared to that of enzalutamide monotherapy (control) 301 over a seven-week period ( Fig 6A) . However, there were no synergistic effect between PKF118-302 310 and PTHrP antagonist, PTHrP . Again, H&E staining showed no significant changes in 303 the histology of the treated xenografts ( Fig 6B) . Immunofluorescence microscopy confirmed the 304 co-localization of TCF4 and PTHrP while MFI measurement demonstrated that PKF118-310 305 treatment decreased PTHrP protein levels ( Fig 6C) . However, PTHrP (7-34) treatment again had no 306 effect on TCF4 expression. Also consistent with the mechanism of action of PKF118-310 in 307 which the interaction between TCF4 and B-catenin is disrupted, PKF118-310 treatment did not alter the expression levels of TCF4. These observations collectively support our concept that 309 TCF4 is an upstream signaling molecule of PTHrP. Supporting the immunofluorescence MFI 310 result, immunoblot revealed a decrease in PTHrP protein levels following PKF118-310 but not 311 PTHrP (7-34) treatment (Fig 6D) levels. Again, no obvious changes in TCF4 protein level was seen 312 with either PFK118-310 or PTHrP administration. Result of the mRNA quantitation for 313 TCF4 and PTHrP was consistent with that of immunoblot ( Fig 6E) . 314 Finally, PKF118-310 and PTHrP as a monotherapy (without enzalutamide) at the 315 same dosage had a more moderate effect on the growth of LNCaP-EnzR xenografts over a six- 316 week period (Supp Fig 4A) . Compared to the vehicle only control group, enzalutamide treatment 317 slightly decreased the tumor growth rate. But this difference was not statistically significant.
318
Again, H&E staining demonstrated no obvious change in histology (Supp Fig 4B) . As seen with 319 above results, immunofluorescence microscopy and MFI showed that PKF118-310 decreased 320 PTHrP but not TCF4 protein levels (Supp Fig 4C) . These observations were supported by the 321 immunoblot (Supp Fig 4D) and QPCR (Supp Fig 4E) . These results collectively suggest that 322 TCF4 and PTHrP inhibitor may be an effective treatment option in the enzalutamide resistant 323 CaP cells. In the present study, we investigated the mechanism of enzalutamide resistance in CaP. After 327 establishing multiple cell lines that are resistant to enzalutamide, NED was identified as a 328 significant event through RNAseq. Subsequently, the transcription factor TCF4 was found to 329 regulate NED which in turn, rendered the cells resistant to enzalutamide in part via PTHrP. In 330 vivo studies confirmed the critical role of TCF4 in enzalutamide resistance and NED.
331
Collectively, these observations demonstrate that enzalutamide stimulates TCF4 transcription 332 which then leads to NED and treatment resistance. More importantly, the in vivo studies suggest 333 that TCF4 may potentially be a new therapeutic target in patients with CRPC.
334
Castration resistance is the ultimate clinical feature of lethal CaP. Despite being resistant 335 to castration, CRPC usually has a clinically significant androgen signaling pathway. This 336 apparent paradox is due to alterations in intracellular androgen synthesis that permit CaP cells to 337 survive and proliferate under low extracellular androgen concentrations (25) (26) (27) . Indeed, the 338 presence of such mechanism in CRPC has been validated clinically with agents such as 339 abiraterone acetate and enzalutamide that target androgen biosynthesis and androgen receptor, 340 respectively (28-30).
341
In treating men with CRPC, enzalutamide is a key second generation anti-androgen used 342 widely due to its ease of administration as well as a low toxicity profile (6). Notwithstanding, as 343 with all second-generation androgen manipulations, resistance to enzalutamide treatment 344 emerges inevitably with a median time of 4.8 months (31) . Although the precise sequence of 345 molecular alterations that result in enzalutamide resistance in CaP remains unclear, it is likely 346 that the mechanism is heterogeneous and involves perturbation of multiple signaling pathways 347 and factors (32-40). One major proposed mechanism is the aberrant expression of AR splice 348 variants, especially AR-V7 (32-34). It has been reported that the level of AR-V7 expression 349 positively correlates with enzalutamide resistance in CaP (32). Another commonly proposed 350 mechanism of enzalutamide resistance is neuroendocrine trans-differentiation. (37, 38, 41) .
351
Specifically, enzalutamide treatment has been associated with the dysregulated transcription 352 factors and genetic abnormalities that lead to . A third class of mechanism of enzalutamide resistance is AR point mutation. Among several well-characterized AR point 354 mutations, T878A (previously T877A) and F877L (previously F876L) have been reported to 355 increase enzalutamide resistance in CaP cell lines (35, 36) . However, AR point mutations do not 356 appear to be a major mechanism of enzalutamide resistance in our experimental models as AR 357 mRNA was completely sequenced in all three enzalutamide-resistant cell lines. Rather, our 358 results suggest NED as the relevant mechanism of enzalutamide resistance in CaP and propose 359 TCF4 as a key molecule in mediating NED in enzalutamide-resistant CaP cells.
360
Although TCF4 is a transcription factor that has been implicated in the canonical β- recently been reported that NED accounts for approximately 25% of lethal prostate cancer (51).
373
Whether TCF4 is involved in all NE-like CaP requires further investigation.
374
The current study also shed additional light on the mechanistic link between NED and 375 enzalutamide resistance. Using RNAseq as well as overexpression and neutralization studies, we 376 have observed that the transcription factor TCF4 mediates NED upon enzalutamide treatment. Of 377 the NED markers, we have focused on PTHrP for the subsequently functional studies because 378 PTHrP has previously been reported to mediate castration resistance (19) . In this regard, our data 379 also support this concept as neutralization of PTHrP reversed enzalutamide resistance. In 380 addition to blocking PTHrP, we have observed that the TCF4 inhibitor (PKF118-310) increased 381 enzalutamide sensitivity and decreased PTHrP protein levels in enzalutamide resistant CaP cell 382 lines in tissue culture and in vivo. Therefore, disrupting the NED axis by targeting either TCF4 or 383 PTHrP may be an effective therapeutic approach in treating CRPC.
384
Despite the potentially significant implications of the current study, our findings should 385 be accepted with caution for the following reasons. First, there are multiple second-generation 386 anti-androgens. Thus, additional studies are needed to determine whether TCF4-mediated NED 387 is a class-specific effect. Second, the molecular connection between TCF4 and enzalutamide is 388 not clear. Currently, we are exploring a potential interaction between androgen receptor and 389 TCF4.
390
In conclusion, the present study suggests that TCF4 mediates enzalutamide resistance via 391 a Wnt-independent pathway. In addition, we have observed that blocking NED via TCF4 or 392 PTHrP inhibitors is potentially therapeutic. In the future, we plan to continue uncovering the 393 molecular link between enzalutamide and TCF4/NED as well as further characterizing the 394 therapeutic potential of blocking TCF4 or PTHrP. 
